461 related articles for article (PubMed ID: 23395844)
1. Preclinical evaluation of zoledronate using an in vitro mimetic cellular model for breast cancer metastatic bone disease.
Dedes PG; Kanakis I; Gialeli Ch; Theocharis AD; Tsegenidis T; Kletsas D; Tzanakakis GN; Karamanos NK
Biochim Biophys Acta; 2013 Jun; 1830(6):3625-34. PubMed ID: 23395844
[TBL] [Abstract][Full Text] [Related]
2. The combined use of Camellia sinensis and metronomic zoledronic acid in a breast cancer-induced osteolysis mouse model.
Luo KW; Ko CH; Yue GG; Gao S; Lee JK; Li G; Fung KP; Leung PC; Evdokiou A; Lau CB
J Cancer Res Clin Oncol; 2015 Jun; 141(6):1025-36. PubMed ID: 25431338
[TBL] [Abstract][Full Text] [Related]
3. Cocultures of osteoblasts and osteoclasts are influenced by local application of zoledronic acid incorporated in a poly(D,L-lactide) implant coating.
Greiner S; Kadow-Romacker A; Schmidmaier G; Wildemann B
J Biomed Mater Res A; 2009 Oct; 91(1):288-95. PubMed ID: 18980195
[TBL] [Abstract][Full Text] [Related]
4. CSF-1 blockade impairs breast cancer osteoclastogenic potential in co-culture systems.
Liverani C; Mercatali L; Spadazzi C; La Manna F; De Vita A; Riva N; Calpona S; Ricci M; Bongiovanni A; Gunelli E; Zanoni M; Fabbri F; Zoli W; Amadori D; Ibrahim T
Bone; 2014 Sep; 66():214-22. PubMed ID: 24956020
[TBL] [Abstract][Full Text] [Related]
5. Expression of matrix macromolecules and functional properties of breast cancer cells are modulated by the bisphosphonate zoledronic acid.
Dedes PG; Gialeli Ch; Tsonis AI; Kanakis I; Theocharis AD; Kletsas D; Tzanakakis GN; Karamanos NK
Biochim Biophys Acta; 2012 Dec; 1820(12):1926-39. PubMed ID: 22884656
[TBL] [Abstract][Full Text] [Related]
6. Adoptive transfer of ex vivo expanded Vγ9Vδ2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer.
Zysk A; DeNichilo MO; Panagopoulos V; Zinonos I; Liapis V; Hay S; Ingman W; Ponomarev V; Atkins G; Findlay D; Zannettino A; Evdokiou A
Cancer Lett; 2017 Feb; 386():141-150. PubMed ID: 27865798
[TBL] [Abstract][Full Text] [Related]
7. Metal-Organic Framework Nanoparticles for Ameliorating Breast Cancer-Associated Osteolysis.
Pang Y; Fu Y; Li C; Wu Z; Cao W; Hu X; Sun X; He W; Cao X; Ling D; Li Q; Fan C; Yang C; Kong X; Qin A
Nano Lett; 2020 Feb; 20(2):829-840. PubMed ID: 31916446
[TBL] [Abstract][Full Text] [Related]
8. Gallium, a promising candidate to disrupt the vicious cycle driving osteolytic metastases.
Strazic-Geljic I; Guberovic I; Didak B; Schmid-Antomarchi H; Schmid-Alliana A; Boukhechba F; Bouler JM; Scimeca JC; Verron E
Biochem Pharmacol; 2016 Sep; 116():11-21. PubMed ID: 27378505
[TBL] [Abstract][Full Text] [Related]
9. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases.
Hiraga T; Williams PJ; Mundy GR; Yoneda T
Cancer Res; 2001 Jun; 61(11):4418-24. PubMed ID: 11389070
[TBL] [Abstract][Full Text] [Related]
10. RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model.
Canon J; Bryant R; Roudier M; Branstetter DG; Dougall WC
Breast Cancer Res Treat; 2012 Oct; 135(3):771-80. PubMed ID: 22926264
[TBL] [Abstract][Full Text] [Related]
11. Skeletal-related events and clinical outcomes in patients with bone metastases and normal levels of osteolysis: exploratory analyses.
Lipton A; Cook R; Brown J; Body JJ; Smith M; Coleman R
Clin Oncol (R Coll Radiol); 2013 Apr; 25(4):217-26. PubMed ID: 23219232
[TBL] [Abstract][Full Text] [Related]
12. Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo.
Wright LE; Harhash AA; Kozlow WM; Waning DL; Regan JN; She Y; John SK; Murthy S; Niewolna M; Marks AR; Mohammad KS; Guise TA
Oncotarget; 2017 Jan; 8(5):8406-8419. PubMed ID: 28039445
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of a cathepsin K inhibitor in a preclinical model for prevention and treatment of breast cancer bone metastasis.
Duong LT; Wesolowski GA; Leung P; Oballa R; Pickarski M
Mol Cancer Ther; 2014 Dec; 13(12):2898-909. PubMed ID: 25249554
[TBL] [Abstract][Full Text] [Related]
14. Plumbagin inhibits breast tumor bone metastasis and osteolysis by modulating the tumor-bone microenvironment.
Li Z; Xiao J; Wu X; Li W; Yang Z; Xie J; Xu L; Cai X; Lin Z; Guo W; Luo J; Liu M
Curr Mol Med; 2012 Sep; 12(8):967-81. PubMed ID: 22574935
[TBL] [Abstract][Full Text] [Related]
15. The bone biologic effects of zoledronate in healthy dogs and dogs with malignant osteolysis.
Fan TM; de Lorimier LP; Garrett LD; Lacoste HI
J Vet Intern Med; 2008; 22(2):380-7. PubMed ID: 18346146
[TBL] [Abstract][Full Text] [Related]
16. Bone-Seeking Matrix Metalloproteinase-2 Inhibitors Prevent Bone Metastatic Breast Cancer Growth.
Tauro M; Shay G; Sansil SS; Laghezza A; Tortorella P; Neuger AM; Soliman H; Lynch CC
Mol Cancer Ther; 2017 Mar; 16(3):494-505. PubMed ID: 28069877
[TBL] [Abstract][Full Text] [Related]
17. Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo.
Ottewell PD; Wang N; Brown HK; Reeves KJ; Fowles CA; Croucher PI; Eaton CL; Holen I
Clin Cancer Res; 2014 Jun; 20(11):2922-32. PubMed ID: 24687923
[TBL] [Abstract][Full Text] [Related]
18. Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment.
Mundy GR; Yoneda T; Hiraga T
Semin Oncol; 2001 Apr; 28(2 Suppl 6):35-44. PubMed ID: 11346863
[TBL] [Abstract][Full Text] [Related]
19. Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity.
Lipton A; Cook RJ; Major P; Smith MR; Coleman RE
Oncologist; 2007 Sep; 12(9):1035-43. PubMed ID: 17914073
[TBL] [Abstract][Full Text] [Related]
20. Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells.
Mancino AT; Klimberg VS; Yamamoto M; Manolagas SC; Abe E
J Surg Res; 2001 Sep; 100(1):18-24. PubMed ID: 11516200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
